6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid | 920023-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid
• 英文别名: 6-chloro-1-[2-(methylamino)-2-oxoethyl]indole-3-carboxylic acid
• CAS: 920023-68-3
• 化学式: C₁₂H₁₁ClN₂O₃
• 分子量: 266.684
• InChiKey: XCBBQOZHNBCCTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid 、 1,3-二氢-1-(-4-哌啶基)(2H)吲哚-2-酮 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-{6-Chloro-3-[4-(2-oxo-2,3-dihydro-indol-1-yl)-piperidine-1-carbonyl]-indol-1-yl}-N-methyl-acetamide
  参考文献：
  名称：

  INDOLES

  摘要：

  本发明涉及新型吲哚-3-基-羰基-哌啶-苯并吡咯酮、苯并噁唑酮和苯并三唑衍生物作为V1a受体拮抗剂，它们的制备、含有它们的药物组合物以及它们用于治疗焦虑和抑郁症等疾病的用途。具体而言，本发明涉及具有式(I)的化合物，其中X、Y和R1至R10如规范中所述。

  公开号：

  US20080161315A1
• 作为产物：
  描述：

  2-[6-Chloro-3-(2,2,2-trifluoro-acetyl)-indol-1-yl]-N-methyl-acetamide 在 sodium trimethylsilanolate 作用下， 以 DCE 为溶剂， 反应 0.33h， 以27%的产率得到6-Chloro-1-methylcarbamoylmethyl-1H-indole-3-carboxylic acid
  参考文献：
  名称：

  INDOLES

  摘要：

  本发明涉及新型吲哚-3-基-羰基-哌啶-苯并吡咯酮、苯并噁唑酮和苯并三唑衍生物作为V1a受体拮抗剂，它们的制备、含有它们的药物组合物以及它们用于治疗焦虑和抑郁症等疾病的用途。具体而言，本发明涉及具有式(I)的化合物，其中X、Y和R1至R10如规范中所述。

  公开号：

  US20080161315A1

文献信息

• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• Indol-3-y-carbonyl-piperidin and piperazin-derivatives
  申请人：Bissantz Caterina

  公开号：US20070027163A1

  公开（公告）日：2007-02-01

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哒-3-基甲酰哌啶和哌嗪衍生物，其由以下式I表示：其中残基R1至R3如本文所定义。该发明还涉及含有这种化合物的药物组合物，以及制备这些化合物和组合物的方法。该发明还涉及治疗痛经、高血压、慢性心力衰竭、抗利尿素过度分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• Indol-3-yl-carbonyl-spiro-piperidine derivatives
  申请人：Bissantz Caterina

  公开号：US20070155761A1

  公开（公告）日：2007-07-05

  This invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as Via receptor antagonists and which are represented by Formula I: wherein the spiropiperidine-head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and to methods of preparation thereof.

  本发明涉及indol-3-yl-carbonyl-spiro-piperidine衍生物，其作为Via受体拮抗剂，并由式I所表示：其中spiropiperidine头基A和残基R1、R2和R3的定义如本文所述。本发明还涉及含有这种化合物的制药组合物，它们在治疗痛经、高血压、慢性心力衰竭、非适当分泌利尿素、肝硬化、肾病综合征、强迫症、焦虑和抑郁症方面的应用，以及其制备方法。
• INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS
  申请人：Bissantz Caterina

  公开号：US20080146557A1

  公开（公告）日：2008-06-19

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及一种作为V1a受体拮抗剂的吲哚-3-基-羰基-螺-哌啶衍生物，其由式I表示：其中，螺-哌啶头基A和残基R1、R2和R3如本文所定义。本发明还涉及含有这种化合物的药物组合物、制备这种化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、抗利尿激素不适当分泌、肝硬化、肾病综合征、强迫症和焦虑抑郁症方面的用途。
• INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20120040990A1

  公开（公告）日：2012-02-16

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及一种作为V1a受体拮抗剂的吲哚-3-基甲酰基哌啶和哌嗪衍生物，其由式I表示：其中残基R1至R3如本文所定义。本发明还涉及含有此类化合物的制药组合物，以及制备该化合物和组合物的方法。本发明还涉及治疗痛经、高血压、慢性心力衰竭、不适当分泌加压素、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。